{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:30:01Z","timestamp":1786987801210,"version":"build-2736575974"},"reference-count":179,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Resistance Updates"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.drup.2022.100805","type":"journal-article","created":{"date-parts":[[2022,1,21]],"date-time":"2022-01-21T02:16:29Z","timestamp":1642731389000},"page":"100805","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"special_numbering":"C","title":["Different mechanisms of drug resistance to hypomethylating agents in the treatment of myelodysplastic syndromes and acute myeloid leukemia"],"prefix":"10.1016","volume":"61","author":[{"given":"Krist\u00edna","family":"\u0160imoni\u010dov\u00e1","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u013dubo\u0161","family":"Janotka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Kavcov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zdena","family":"Sulov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Breier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Messingerova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drup.2022.100805_bib0005","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2012.30","article-title":"Imidazoacridinone-dependent lysosomal photodestruction: a pharmacological Trojan horse approach to eradicate multidrug-resistant cancers","volume":"3","author":"Adar","year":"2012","journal-title":"Cell Death Dis."},{"issue":"1","key":"10.1016\/j.drup.2022.100805_bib0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2193-1801-3-732","article-title":"Overexpression of MRP4 (ABCC4) and MRP5 (ABCC5) confer resistance to the nucleoside analogs cytarabine and troxacitabine, but not gemcitabine","volume":"3","author":"Adema","year":"2014","journal-title":"Springer Plus"},{"issue":"22","key":"10.1016\/j.drup.2022.100805_bib0015","doi-asserted-by":"crossref","first-page":"5229","DOI":"10.1182\/blood-2011-11-382226","article-title":"RNA-dependent inhibition of ribonucleotide reductase is a major pathway for 5-azacytidine activity in acute myeloid leukemia","volume":"119","author":"Aimiuwu","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.drup.2022.100805_bib0020","doi-asserted-by":"crossref","first-page":"404","DOI":"10.3324\/haematol.2018.188094","article-title":"Efficacy of the combination of venetoclax and hypomethylating agents in relapsed\/refractory acute myeloid leukemia","author":"Aldoss","year":"2018","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.drup.2022.100805_bib0025","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.clml.2016.10.003","article-title":"Evidence for selective benefit of sequential treatment with hypomethylating agents in patients with myelodysplastic syndrome","volume":"17","author":"Apuri","year":"2017","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"August","key":"10.1016\/j.drup.2022.100805_bib0030","doi-asserted-by":"crossref","first-page":"100645","DOI":"10.1016\/j.drup.2019.100645","article-title":"The multi-factorial nature of clinical multidrug resistance in cancer","volume":"46","author":"Assaraf","year":"2019","journal-title":"Drug Resist. Updates"},{"issue":"9","key":"10.1016\/j.drup.2022.100805_bib0035","doi-asserted-by":"crossref","first-page":"3679","DOI":"10.1182\/blood-2004-06-2459","article-title":"FLT3-ITD-TKD dual mutants associated with AML confer resistance to FLT3 PTK inhibitors and cytotoxic agents by overexpression of Bcl-x(L)","volume":"105","author":"Bagrintseva","year":"2005","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.drup.2022.100805_bib0040","doi-asserted-by":"crossref","first-page":"15880","DOI":"10.1074\/jbc.M414337200","article-title":"Functional characterization of novel human and mouse equilibrative nucleoside transporters (hENT3 and mENT3) located in intracellular membranes","volume":"280","author":"Baldwin","year":"2005","journal-title":"J. Biol. Chem."},{"issue":"12","key":"10.1016\/j.drup.2022.100805_bib0045","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1172\/JCI119849","article-title":"Constitutive nuclear factor-\u03bab-RelA activation is required for proliferation and survival of Hodgkin\u2019s disease tumor cells","volume":"100","author":"Bargou","year":"1997","journal-title":"J. Clin. Invest."},{"issue":"49","key":"10.1016\/j.drup.2022.100805_bib0050","doi-asserted-by":"crossref","first-page":"6910","DOI":"10.1038\/sj.onc.1203238","article-title":"Control of apoptosis by Rel\/NF-\u03baB transcription factors","volume":"18","author":"Barkett","year":"1999","journal-title":"Oncogene"},{"issue":"5","key":"10.1016\/j.drup.2022.100805_bib0055","doi-asserted-by":"crossref","first-page":"547","DOI":"10.3109\/07357909009012080","article-title":"The clinical relevance of multidrug resistance","volume":"8","author":"Bellamy","year":"1990","journal-title":"Cancer Invest."},{"issue":"3","key":"10.1016\/j.drup.2022.100805_bib0060","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1152\/physrev.1999.79.3.763","article-title":"Sodium\/Calcium exchange\u202f: its physiological implications","volume":"79","author":"Blaustein","year":"1999","journal-title":"Physiol. Rev."},{"issue":"22","key":"10.1016\/j.drup.2022.100805_bib0065","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1038\/onc.2009.69","article-title":"Suppression of the DNA damage response in acute myeloid leukemia versus myelodysplastic syndrome","volume":"28","author":"Boehrer","year":"2009","journal-title":"Oncogene"},{"issue":"8","key":"10.1016\/j.drup.2022.100805_bib0070","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1038\/leu.2014.44","article-title":"BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignancies","volume":"28","author":"Bogenberger","year":"2014","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.drup.2022.100805_bib0075","doi-asserted-by":"crossref","first-page":"226","DOI":"10.3109\/10428194.2014.910657","article-title":"Ex vivo activity of BCL-2 family inhibitors ABT-199 and ABT-737 combined with 5-azacytidine in myeloid malignancies","volume":"56","author":"Bogenberger","year":"2015","journal-title":"Leuk. Lymphoma"},{"issue":"5","key":"10.1016\/j.drup.2022.100805_bib0080","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s00424-006-0054-9","article-title":"Multidrug resistance-associated proteins 3, 4, and 5","volume":"453","author":"Borst","year":"2007","journal-title":"Pflugers Archiv Eur. J. Physiol."},{"issue":"4","key":"10.1016\/j.drup.2022.100805_bib0085","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1080\/10428190701882146","article-title":"Activity of decitabine in patients with myelodysplastic syndrome previously treated with azacitidine","volume":"49","author":"Borthakur","year":"2008","journal-title":"Leuk. Lymphoma"},{"issue":"6","key":"10.1016\/j.drup.2022.100805_bib0090","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"issue":"1","key":"10.1016\/j.drup.2022.100805_bib0095","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2174\/187152013804487380","article-title":"New insight into P-Glycoprotein as a drug target","volume":"13","author":"Breier","year":"2013","journal-title":"Anticancer Agents Med. Chem."},{"key":"10.1016\/j.drup.2022.100805_bib0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.mrgentox.2021.503385","article-title":"Exposure to hypomethylating 5-aza-2\u2032-deoxycytidine (decitabine) causes rapid, severe DNA damage, telomere elongation and mitotic dysfunction in human WIL2-NS cells","author":"Bull","year":"2021","journal-title":"Mutation Res. Genet. Toxicol. Environ. Mutagenesis"},{"issue":"11","key":"10.1016\/j.drup.2022.100805_bib0105","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1182\/blood.V81.11.3091.3091","article-title":"High expression of Bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy","volume":"81","author":"Campos","year":"1993","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.drup.2022.100805_bib0110","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/s41571-020-0341-y","article-title":"Targeting apoptosis in cancer therapy","volume":"17","author":"Carneiro","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.drup.2022.100805_bib0115","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1182\/blood-2004-11-4286","article-title":"The FA\/BRCA pathway is involved in melphalan-induced DNA interstrand cross-link repair and accounts for melphalan resistance in multiple myeloma cells","volume":"106","author":"Chen","year":"2005","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.drup.2022.100805_bib0120","first-page":"1","article-title":"RNA cytosine methylation and methyltransferases mediate chromatin organization and 5-azacytidine response and resistance in leukaemia","volume":"9","author":"Cheng","year":"2018","journal-title":"Nat. Commun."},{"issue":"11","key":"10.1016\/j.drup.2022.100805_bib0125","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1158\/1078-0432.CCR-13-0483","article-title":"Gender, cytidine deaminase, and 5-aza\/decitabine - Letter","volume":"19","author":"Ciccolini","year":"2013","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.drup.2022.100805_bib0130","doi-asserted-by":"crossref","first-page":"490","DOI":"10.18632\/oncotarget.481","article-title":"BCL2L10 is a predictive factor for resistance to Azacitidine in MDS and AML patients","volume":"3","author":"Cluzeau","year":"2012","journal-title":"Oncotarget"},{"issue":"12","key":"10.1016\/j.drup.2022.100805_bib0135","doi-asserted-by":"crossref","first-page":"4384","DOI":"10.18632\/oncotarget.2024","article-title":"Phenotypic and genotypic characterization of azacitidine-sensitive and resistant SKM1 myeloid cell lines","volume":"5","author":"Cluzeau","year":"2014","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.drup.2022.100805_bib0140","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1007\/s11899-015-0269-y","article-title":"Incidence and burden of the myelodysplastic syndromes","volume":"10","author":"Cogle","year":"2015","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"10.1016\/j.drup.2022.100805_bib0145","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.molcel.2019.05.036","article-title":"IKK\u03b1 kinase regulates the DNA damage response and drives chemo-resistance in Cancer","volume":"75","author":"Colomer","year":"2019","journal-title":"Mol. Cell"},{"issue":"7","key":"10.1016\/j.drup.2022.100805_bib0150","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.1073\/pnas.1324297111","article-title":"Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission","volume":"111","author":"Corces-Zimmerman","year":"2014","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"5","key":"10.1016\/j.drup.2022.100805_bib0155","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1038\/leu.2012.312","article-title":"Azacitidine fails to eradicate leukemic stem\/progenitor cell populations in patients with acute myeloid leukemia and myelodysplasia","volume":"27","author":"Craddock","year":"2013","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.drup.2022.100805_bib0160","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1080\/15257770.2011.652330","article-title":"Role of human nucleoside transporters in the uptake and cytotoxicity of azacitidine and decitabine","volume":"31","author":"Damaraju","year":"2012","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"issue":"1","key":"10.1016\/j.drup.2022.100805_bib0165","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cancers11010119","article-title":"Platinum resistance in ovarian cancer: role of DNA repair","volume":"11","author":"Damia","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.drup.2022.100805_bib0170","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.cancergen.2020.12.002","article-title":"DNA damaging agents and DNA repair: from carcinogenesis to cancer therapy","volume":"252\u2013253","author":"de Almeida","year":"2021","journal-title":"Cancer Genet."},{"key":"10.1016\/j.drup.2022.100805_bib0175","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1007\/s40262-020-00934-7","article-title":"Intracellular Pharmacokinetics of Pyrimidine Analogues used in Oncology and the Correlation with Drug Action","volume":"59","author":"Derissen","year":"2020","journal-title":"Clin. Pharmacokinet."},{"issue":"1","key":"10.1016\/j.drup.2022.100805_bib0180","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13148-016-0237-y","article-title":"A clinical-molecular update on azanucleoside-based therapy for the treatment of hematologic cancers","volume":"8","author":"Diesch","year":"2016","journal-title":"Clin. Epigenetics"},{"key":"10.1016\/j.drup.2022.100805_bib0185","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S1470-2045(18)30010-X","article-title":"Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia\u202f: a non-randomised, open-label, phase 1b study","volume":"19","author":"DiNardo","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.drup.2022.100805_bib0190","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/ajh.25000","article-title":"Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies","volume":"93","author":"DiNardo","year":"2018","journal-title":"Am. J. Hematol."},{"issue":"07","key":"10.1016\/j.drup.2022.100805_bib0195","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.drup.2022.100805_bib0200","doi-asserted-by":"crossref","first-page":"e724","DOI":"10.1016\/S2352-3026(20)30210-6","article-title":"10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial","volume":"7","author":"DiNardo","year":"2020","journal-title":"Lancet Haematol."},{"issue":"12","key":"10.1016\/j.drup.2022.100805_bib0205","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMra1406184","article-title":"Acute myeloid leukemia","volume":"373","author":"D\u00f6hner","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.drup.2022.100805_bib0210","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/0006-291X(70)90619-4","article-title":"The Effects of 5-Azacytidine and 5-Azauridine on Protein Synthesis in Escherichia coli","volume":"38","author":"Dosko\u010dil","year":"1970","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"2","key":"10.1016\/j.drup.2022.100805_bib0215","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1053\/jhep.2000.9546","article-title":"Selective loss of nucleoside carrier expression in rat hepatocarcinomas","volume":"32","author":"Dragan","year":"2000","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.drup.2022.100805_bib0220","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/cts.12366","article-title":"ABCC4 is a determinant of cytarabine-induced cytotoxicity and myelosuppression","volume":"9","author":"Drenberg","year":"2016","journal-title":"Clin. Transl. Sci."},{"issue":"2","key":"10.1016\/j.drup.2022.100805_bib0225","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s12185-019-02651-9","article-title":"Clinical update on hypomethylating agents","volume":"110","author":"Duchmann","year":"2019","journal-title":"Int. J. Hematol."},{"issue":"6","key":"10.1016\/j.drup.2022.100805_bib0230","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.3109\/10428194.2014.966708","article-title":"Lack of objective response of myelodysplastic syndromes and acute myeloid leukemia to decitabine after failure of azacitidine","volume":"56","author":"Duong","year":"2014","journal-title":"Leuk. Lymphoma"},{"issue":"23","key":"10.1016\/j.drup.2022.100805_bib0235","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1182\/blood.V126.23.678.678","article-title":"Mechanisms of resistance to 5-Azacytidine\/Decitabine in MDS-AML and pre-clinical in vivo proof of principle of rational solutions to extend response","volume":"126","author":"Ebrahem","year":"2015","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.drup.2022.100805_bib0240","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s00412-014-0482-9","article-title":"DNA damage accumulation and repair defects in acute myeloid leukemia: Implications for pathogenesis, disease progression, and chemotherapy resistance","volume":"123","author":"Esposito","year":"2014","journal-title":"Chromosoma"},{"issue":"6","key":"10.1016\/j.drup.2022.100805_bib0245","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1158\/0008-5472.CAN-03-2932","article-title":"Allelic imbalance of 12q22-23 associated with APAF-1 locus correlates with poor disease outcome in cutaneous melanoma","volume":"64","author":"Fujimoto","year":"2004","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.drup.2022.100805_bib0250","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1002\/ijc.24064","article-title":"Tumor resistance to apoptosis","volume":"124","author":"Fulda","year":"2009","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.drup.2022.100805_bib0255","doi-asserted-by":"crossref","first-page":"5865","DOI":"10.1038\/sj.onc.1204750","article-title":"Sensitization for death-receptor- or drug-induced apoptosis by re-expression of caspase-8 through demethylation or gene transfer","volume":"20","author":"Fulda","year":"2001","journal-title":"Oncogene"},{"issue":"6","key":"10.1016\/j.drup.2022.100805_bib0260","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1158\/1541-7786.MCR-04-0105","article-title":"Methylation silencing of the Apaf-1 gene in acute leukemia","volume":"3","author":"Furukawa","year":"2005","journal-title":"Mol. Cancer Res."},{"issue":"15","key":"10.1016\/j.drup.2022.100805_bib0265","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1038\/onc.2011.384","article-title":"Molecular mechanisms of cisplatin resistance","volume":"31","author":"Galluzzi","year":"2012","journal-title":"Oncogene"},{"issue":"3","key":"10.1016\/j.drup.2022.100805_bib0270","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/s41418-017-0012-4","article-title":"Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018","volume":"25","author":"Galluzzi","year":"2018","journal-title":"Cell Death Differ."},{"issue":"24","key":"10.1016\/j.drup.2022.100805_bib0275","doi-asserted-by":"crossref","first-page":"37331","DOI":"10.18632\/oncotarget.7949","article-title":"The clinical value of aberrant epigenetic changes of DNA damage repair genes in human cancer","volume":"7","author":"Gao","year":"2016","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.drup.2022.100805_bib0280","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1038\/sj.leu.2405070","article-title":"A prognostic score for patients with lower risk myelodysplastic syndrome","volume":"22","author":"Garcia-Manero","year":"2008","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.drup.2022.100805_bib0285","first-page":"3299","article-title":"Role for ATM in DNA damage-induced phosphorylation of BRCA1","volume":"60","author":"Gatei","year":"2000","journal-title":"Cancer Res."},{"key":"10.1016\/j.drup.2022.100805_bib0290","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.drup.2012.07.002","article-title":"Antifolates in cancer therapy: structure, activity and mechanisms of drug resistance","volume":"15","author":"Gonen","year":"2012","journal-title":"Drug Resist. Updates"},{"issue":"23","key":"10.1016\/j.drup.2022.100805_bib0295","doi-asserted-by":"crossref","first-page":"7337","DOI":"10.1158\/1078-0432.CCR-11-1667","article-title":"Lysosomal sequestration of sunitinib: a novel mechanism of drug resistance","volume":"17","author":"Gotink","year":"2011","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.drup.2022.100805_bib0300","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/nrc706","article-title":"Multidrug resistance in cancer: role of ATP-dependent transporters","volume":"2","author":"Gottesman","year":"2002","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.drup.2022.100805_bib0305","first-page":"5505","article-title":"Effect of Uridine on response of 5-Azacytidine-resistant human leukemic cells to inhibitors of de novo pyrimidine synthesis","volume":"44","author":"Grant","year":"1984","journal-title":"Cancer Res."},{"issue":"8","key":"10.1016\/j.drup.2022.100805_bib0310","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1358\/dof.2013.38.8.1980499","article-title":"SGI-110: DNA methyltransferase inhibitor oncolytic","volume":"38","author":"Griffiths","year":"2013","journal-title":"Drugs Future"},{"key":"10.1016\/j.drup.2022.100805_bib0315","doi-asserted-by":"crossref","first-page":"3388","DOI":"10.1038\/s41375-020-0973-z","article-title":"Distinct and overlapping mechanisms of resistance to azacytidine and guadecitabine in acute myeloid leukemia","volume":"34","author":"Gruber","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.drup.2022.100805_bib0320","article-title":"Decitabine- and 5-azacytidine resistance emerges from adaptive responses of the pyrimidine metabolism network","author":"Gu","year":"2020","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.drup.2022.100805_bib0325","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1158\/1078-0432.CCR-08-0442","article-title":"Expression of ABCC-Type nucleotide exporters in blasts of adult acute myeloid leukemia: relation to long-term survival","volume":"15","author":"Guo","year":"2009","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.drup.2022.100805_bib0330","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.leukres.2015.02.004","article-title":"Outcome of patients with high risk Myelodysplastic Syndrome (MDS) and advanced Chronic Myelomonocytic Leukemia (CMML) treated with decitabine after azacitidine failure","volume":"39","author":"Harel","year":"2015","journal-title":"Leuk. Res."},{"issue":"11","key":"10.1016\/j.drup.2022.100805_bib0335","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1080\/15384101.2017.1314407","article-title":"SAMHD1 protects cancer cells from various nucleoside-based antimetabolites","volume":"16","author":"Herold","year":"2017","journal-title":"Cell Cycle"},{"key":"10.1016\/j.drup.2022.100805_bib0340","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.exphem.2017.05.001","article-title":"With me or against me\u202f: tumor suppressor and drug resistance activities of SAMHD1","volume":"52","author":"Herold","year":"2017","journal-title":"Exp. Hematol."},{"issue":"10","key":"10.1016\/j.drup.2022.100805_bib0345","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1200\/JCO.2006.08.4061","article-title":"Activated intrinsic apoptosis pathway is a key related prognostic parameter in acute myeloid leukemia","volume":"25","author":"Hess","year":"2007","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.drup.2022.100805_bib0350","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1158\/0008-5472.CAN-08-1420","article-title":"Human multidrug resistance protein 7 (ABCC10) is a resistance factor for nucleoside analogs and epothilone B","volume":"69","author":"Hopper-Borge","year":"2009","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.drup.2022.100805_bib0355","doi-asserted-by":"crossref","first-page":"761","DOI":"10.3892\/ol.2015.3253","article-title":"Acquired resistance to decitabine and cross-resistance to gemcitabine during the long-term treatment of human HCT116 colorectal cancer cells with decitabine","volume":"10","author":"Hosokawa","year":"2015","journal-title":"Oncol. Lett."},{"issue":"12","key":"10.1016\/j.drup.2022.100805_bib0360","doi-asserted-by":"crossref","first-page":"4294","DOI":"10.1158\/0008-5472.CAN-03-3884","article-title":"Membrane transporters and channels: role of the transportome in cancer chemosensitivity and chemoresistance","volume":"64","author":"Huang","year":"2004","journal-title":"Cancer Res."},{"issue":"18","key":"10.1016\/j.drup.2022.100805_bib0365","doi-asserted-by":"crossref","first-page":"4267","DOI":"10.1182\/bloodadvances.2020002846","article-title":"Ibrutinib added to 10-day decitabine for older patients with AML and higher risk MDS","volume":"4","author":"Huls","year":"2020","journal-title":"Blood Adv."},{"issue":"3","key":"10.1016\/j.drup.2022.100805_bib0370","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1124\/mol.113.086801","article-title":"The role of human equilibrative nucleoside transporter 1 on the cellular transport of the DNA methyltransferase inhibitors 5-Azacytidine and CP-4200 in human leukemia cells s","volume":"84","author":"Hummel-Eisenbeiss","year":"2013","journal-title":"Mol. Pharmacol."},{"issue":"7","key":"10.1016\/j.drup.2022.100805_bib0375","doi-asserted-by":"crossref","first-page":"11748","DOI":"10.18632\/oncotarget.14342","article-title":"Establishment and characterization of hypomethylating agent resistant cell lines, MOLM\/AZA-1 and MOLM\/DEC-5","volume":"8","author":"Hur","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.drup.2022.100805_bib0380","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2021.100769","article-title":"The role of endolysosomal trafficking in anticancer drug resistance","volume":"57","author":"Hussein","year":"2021","journal-title":"Drug Resist. Updates"},{"issue":"2","key":"10.1016\/j.drup.2022.100805_bib0385","first-page":"513","article-title":"Isolation and characterization of gemcitabine-resistant human non-small cell lung cancer A549 cells","volume":"38","author":"Ikeda","year":"2011","journal-title":"Int. J. Oncol."},{"issue":"3","key":"10.1016\/j.drup.2022.100805_bib0390","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.bcp.2014.03.008","article-title":"Constitutive activation of the ATM\/BRCA1 pathway prevents DNA damage-induced apoptosis in 5-azacytidine-resistant cell lines","volume":"89","author":"Imanishi","year":"2014","journal-title":"Biochem. Pharmacol."},{"issue":"41","key":"10.1016\/j.drup.2022.100805_bib0395","doi-asserted-by":"crossref","first-page":"69906","DOI":"10.18632\/oncotarget.19436","article-title":"Teriflunomide restores 5-azacytidine sensitivity via activation of pyrimidine salvage in 5-azacytidine-resistant leukemia cells","volume":"8","author":"Imanishi","year":"2017","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.drup.2022.100805_bib0400","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1080\/10245330290011838","article-title":"Bcl-2 family members as prognostic indicators in AML","volume":"7","author":"Irvine","year":"2002","journal-title":"Hematology"},{"key":"10.1016\/j.drup.2022.100805_bib0405","series-title":"Topics on Drug Metabolism","first-page":"35","article-title":"Phase II drug metabolism","author":"Jan\u010dova","year":"2012"},{"issue":"4","key":"10.1016\/j.drup.2022.100805_bib0410","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijms22042076","article-title":"Changes in apoptotic pathways in molm\u201013 cell lines after induction of resistance to hypomethylating agents","volume":"22","author":"Janotka","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"25","key":"10.1016\/j.drup.2022.100805_bib0415","doi-asserted-by":"crossref","first-page":"11797","DOI":"10.1073\/pnas.91.25.11797","article-title":"Toxicity of 5-aza-2\u2019-deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation","volume":"91","author":"Juttermann","year":"1994","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.drup.2022.100805_bib0420","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s13353-019-00516-9","article-title":"DNA repair in cancer initiation, progression, and therapy\u2014a double-edged sword","volume":"60","author":"Kiwerska","year":"2019","journal-title":"J. Appl. Genet."},{"issue":"6","key":"10.1016\/j.drup.2022.100805_bib0425","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1158\/1078-0432.CCR-09-2551","article-title":"Highly phosphorylated FOXO3A is an adverse prognostic factor in acute myeloid leukemia","volume":"16","author":"Kornblau","year":"2010","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.drup.2022.100805_bib0430","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/s00424-006-0114-1","article-title":"ABCC10, ABCC11, and ABCC12","volume":"453","author":"Kruh","year":"2007","journal-title":"Pflugers Archiv Eur. J. Physiol."},{"issue":"6","key":"10.1016\/j.drup.2022.100805_bib0435","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cancers10060158","article-title":"Beyond the edge of hypomethylating agents: Novel combination strategies for older adults with advanced MDS and AML","volume":"10","author":"Kubasch","year":"2018","journal-title":"Cancers"},{"issue":"45","key":"10.1016\/j.drup.2022.100805_bib0440","doi-asserted-by":"crossref","first-page":"27882","DOI":"10.18632\/oncotarget.25328","article-title":"Efficacy of azacitidine is independent of molecular and clinical characteristics-an analysis of 128 patients with myelodysplastic syndromes or acute myeloid leukemia and a review of the literature","volume":"9","author":"Kuendgen","year":"2018","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.drup.2022.100805_bib0445","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.stem.2012.12.013","article-title":"BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells","volume":"12","author":"Lagadinou","year":"2013","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.drup.2022.100805_bib0450","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2020.100704","article-title":"Nanomedicine to target multidrug resistant tumors","volume":"52","author":"Lepeltier","year":"2020","journal-title":"Drug Resist. Updates"},{"key":"10.1016\/j.drup.2022.100805_bib0455","doi-asserted-by":"crossref","DOI":"10.1038\/s41419-019-1626-x","article-title":"Surmounting Cytarabine-resistance in acute myeloblastic leukemia cells and specimens with a synergistic combination of hydroxyurea and azidothymidine","volume":"10","author":"Levin","year":"2019","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.drup.2022.100805_bib0460","doi-asserted-by":"crossref","DOI":"10.1186\/s12935-021-01746-w","article-title":"Deciphering molecular mechanisms underlying chemoresistance in relapsed AML patients: towards precision medicine overcoming drug resistance","volume":"21","author":"Levin","year":"2021","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.drup.2022.100805_bib0465","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.drup.2016.05.001","article-title":"Overcoming ABC transporter-mediated multidrug resistance: molecular mechanisms and novel therapeutic drug strategies","volume":"27","author":"Li","year":"2016","journal-title":"Drug Resist. Updates"},{"issue":"104","key":"10.1016\/j.drup.2022.100805_bib0470","article-title":"Critical role of FOXO3a in carcinogenesis","volume":"17","author":"Liu","year":"2018","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.drup.2022.100805_bib0475","series-title":"Pathology and Epidemiology of Cancer","author":"Loda","year":"2017"},{"issue":"2","key":"10.1016\/j.drup.2022.100805_bib0480","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1002\/path.1706","article-title":"Molecular mechanisms of drug resistance","volume":"205","author":"Longley","year":"2005","journal-title":"J. Pathol."},{"issue":"3","key":"10.1016\/j.drup.2022.100805_bib0485","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1200\/JCO.19.01053","article-title":"Valproate and retinoic acid in combination with decitabine in elderly nonfit patients with acute myeloid leukemia: results of a multicenter, randomized, 2 \u00d7 2, phase II trial","volume":"38","author":"L\u00fcbbert","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.drup.2022.100805_bib0490","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1158\/1535-7163.MCT-10-0309","article-title":"Combinations of DNA methyltransferase and histone deacetylase inhibitors induce DNA damage in small cell lung cancer cells: correlation of resistance with IFN-stimulated gene expression","volume":"9","author":"Luszczek","year":"2010","journal-title":"Mol. Cancer Ther."},{"issue":"3","key":"10.1016\/j.drup.2022.100805_bib0495","first-page":"1136","article-title":"The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents","volume":"9","author":"Ma","year":"2003","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.drup.2022.100805_bib0500","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1158\/1078-0432.CCR-12-1722","article-title":"Increased CDA expression\/activity in males contributes to decreased cytidine analog half-life and likely contributes to worse outcomes with 5-azacytidine or decitabine therapy","volume":"19","author":"Mahfouz","year":"2013","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.drup.2022.100805_bib0505","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-019-0991-5","article-title":"Exosomes: composition, biogenesis, and mechanisms in cancer metastasis and drug resistance","volume":"18","author":"Mashouri","year":"2019","journal-title":"Mol. Cancer"},{"issue":"1","key":"10.1016\/j.drup.2022.100805_bib0510","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3324\/haematol.2017.172353","article-title":"Randomized study of continuous high-dose Lenalidomide, sequential Azacitidine and Lenalidomide, or azacitidine in persons 65 years and over with newly-diagnosed acute myeloid leukemia","volume":"103","author":"Medeiros","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.drup.2022.100805_bib0515","series-title":"The Myelodysplastic Syndromes: Pathobiology and Clinical Management","first-page":"181","article-title":"Different mechanisms of drug resistance in myelodysplastic syndromes and acute myeloid leukemia","author":"Messingerova","year":"2016"},{"issue":"223","key":"10.1016\/j.drup.2022.100805_bib0520","article-title":"Analysis of 5-Azacytidine resistance models reveals a set of","volume":"11","author":"Mina\u0159\u00edk","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.drup.2022.100805_bib0525","first-page":"630","article-title":"Drug resistance and its clinical circumvention","volume":"vol. 8","author":"Moscow","year":"2010"},{"issue":"1","key":"10.1016\/j.drup.2022.100805_bib0530","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/prp2.206","article-title":"Lack of cross-resistance to FF-10501, an inhibitor of inosine-5\u2032-monophosphate dehydrogenase, in azacitidine-resistant cell lines selected from SKM-1 and MOLM-13 leukemia cell lines","volume":"4","author":"Murase","year":"2016","journal-title":"Pharmacol. Res. Perspect."},{"key":"10.1016\/j.drup.2022.100805_bib0535","unstructured":"NCT04140487 (n.d.). Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent\/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome\/Myeloproliferative Neoplasm. Retrieved January 11, 2022, from https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04140487."},{"key":"10.1016\/j.drup.2022.100805_bib0540","unstructured":"NCT04313881 (n.d.). Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Participants With Myelodysplastic Syndrome (MDS). Retrieved January 11, 2022, from https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04313881."},{"issue":"2","key":"10.1016\/j.drup.2022.100805_bib0545","doi-asserted-by":"crossref","first-page":"164","DOI":"10.2174\/1389450115666141122211549","article-title":"Insights into a critical role of the FOXO3a-FOXM1 Axis in DNA damage response and genotoxic drug resistance","volume":"17","author":"Nestal de Moraes","year":"2016","journal-title":"Curr. Drug Targets"},{"issue":"1","key":"10.1016\/j.drup.2022.100805_bib0550","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1093\/annonc\/mdp264","article-title":"Prognostic impact of age and gender in 897 untreated patients with primary myelodysplastic syndromes","volume":"21","author":"N\u00f6sslinger","year":"2010","journal-title":"Ann. Oncol."},{"issue":"7","key":"10.1016\/j.drup.2022.100805_bib0555","doi-asserted-by":"crossref","first-page":"926","DOI":"10.6004\/jnccn.2017.0116","article-title":"Acute myeloid leukemia, version 3.2017: clinical practice guidelines in oncology","volume":"15","author":"O\u2019Donnell","year":"2017","journal-title":"JNCCN J. Nat. Comp. Cancer Network"},{"issue":"1","key":"10.1016\/j.drup.2022.100805_bib0560","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-11413-4","article-title":"Selective inactivation of hypomethylating agents by SAMHD1 provides a rationale for therapeutic stratification in AML","volume":"10","author":"Oellerich","year":"2019","journal-title":"Nat. Commun."},{"issue":"6","key":"10.1016\/j.drup.2022.100805_bib0565","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/j.1365-2184.2012.00845.x","article-title":"Programmed cell death pathways in cancer: a review of apoptosis, autophagy and programmed necrosis","volume":"45","author":"Ouyang","year":"2012","journal-title":"Cell Prolif."},{"issue":"2","key":"10.1016\/j.drup.2022.100805_bib0570","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1128\/MCB.01799-07","article-title":"DNA methylation inhibitor 5-Aza-2\u2019-deoxycytidine induces reversible genome-wide DNA damage that is distinctly influenced by DNA methyltransferases 1 and 3B","volume":"28","author":"Palii","year":"2008","journal-title":"Mol. Cell. Biol."},{"issue":"3","key":"10.1016\/j.drup.2022.100805_bib0575","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1158\/2159-8290.CD-13-0609","article-title":"Selective BCL-2 inhibition by ABT-199 causes on target cell death in acute myeloid leukemia","volume":"4","author":"Pan","year":"2014","journal-title":"Cancer Discov."},{"issue":"10","key":"10.1016\/j.drup.2022.100805_bib0580","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1093\/carcin\/bgs167","article-title":"FOXM1 mediates Dox resistance in breast cancer by enhancing DNA repair","volume":"33","author":"Park","year":"2012","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.drup.2022.100805_bib0585","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2018.00606","article-title":"Emerging roles of nucleoside transporters","volume":"9","author":"Pastor-Anglada","year":"2018","journal-title":"Front. Pharmacol."},{"issue":"11","key":"10.1016\/j.drup.2022.100805_bib0590","doi-asserted-by":"crossref","first-page":"3224","DOI":"10.1158\/0008-5472.CAN-15-2249","article-title":"Combined inhibition of DNMT and HDAC blocks the tumorigenicity of cancer stem-like cells and attenuates mammary tumor growth","volume":"76","author":"Pathania","year":"2016","journal-title":"Cancer Res."},{"issue":"October","key":"10.1016\/j.drup.2022.100805_bib0595","first-page":"1","article-title":"Reduced intracellular drug accumulation in drug-resistant leukemia cells is not only solely due to MDR-mediated efflux but also to decreased uptake","volume":"4","author":"Pisco","year":"2014","journal-title":"Front. Oncol."},{"issue":"9","key":"10.1016\/j.drup.2022.100805_bib0600","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1135\/cccc19642060","article-title":"Nucleic acids components and their analogues. LI. Synthesis of 1-glycosyl derivatives of 5-azauracil and 5-azacytosine","volume":"29","author":"P\u00edskala","year":"1964","journal-title":"Collect. Czech. Chem. Commun."},{"issue":"9","key":"10.1016\/j.drup.2022.100805_bib0605","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.1111\/febs.15531","article-title":"A guide to plasma membrane solute carrier proteins","volume":"288","author":"Pizzagalli","year":"2021","journal-title":"FEBS J."},{"key":"10.1016\/j.drup.2022.100805_bib0610","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1135\/cccc19642576","article-title":"Synthesis of a 2-deoxy-d-ribofuranosyl-5-azacytosine","volume":"29","author":"Pliml","year":"1964","journal-title":"Collect. Czech. Chem. Commun."},{"issue":"12","key":"10.1016\/j.drup.2022.100805_bib0615","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1038\/s41591-018-0233-1","article-title":"Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia","volume":"24","author":"Pollyea","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.drup.2022.100805_bib0620","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.leukres.2017.03.011","article-title":"Increase of DNA damage and alteration of the DNA damage response in myelodysplastic syndromes and acute myeloid leukemias","volume":"57","author":"Popp","year":"2017","journal-title":"Leuk. Res."},{"issue":"24","key":"10.1016\/j.drup.2022.100805_bib0625","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1200\/JCO.2011.35.8135","article-title":"Outcome of high-risk myelodysplastic syndrome after azacitidine Treatment failure","volume":"29","author":"Pr\u00e9bet","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.drup.2022.100805_bib0630","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.neo.2014.05.007","article-title":"Pathway-centric integrative analysis identifies RRM2 as a prognostic marker in breast Cancer Associated with poor survival and tamoxifen resistance","volume":"16","author":"Putluri","year":"2014","journal-title":"Neoplasia"},{"issue":"3","key":"10.1016\/j.drup.2022.100805_bib0635","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1182\/blood-2008-02-140038","article-title":"Mechanisms of resistance to 5-aza-2\u2019-deoxycytidine in human cancer cell lines","volume":"113","author":"Qin","year":"2009","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.drup.2022.100805_bib0640","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0023372","article-title":"Mechanisms of resistance to decitabine in the myelodysplastic syndrome","volume":"6","author":"Qin","year":"2011","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.drup.2022.100805_bib0645","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1007\/s11899-015-0255-4","article-title":"Targeting the microenvironment in acute myeloid leukemia","volume":"10","author":"Rashidi","year":"2015","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"10.1016\/j.drup.2022.100805_bib0650","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.leukres.2010.04.014","article-title":"3-Deazauridine enhances the antileukemic action of 5-aza-2 -deoxycytidine and targets drug-resistance due to deficiency in deoxycytidine kinase","volume":"35","author":"Raynal","year":"2011","journal-title":"Leuk. Res."},{"issue":"1","key":"10.1016\/j.drup.2022.100805_bib0655","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1158\/1535-7163.MCT-08-0743","article-title":"Human concentrative nucleoside transporter 1-mediated uptake of 5-azacytidine enhances DNA demethylation","volume":"8","author":"Rius","year":"2009","journal-title":"Mol. Cancer Ther."},{"issue":"24","key":"10.1016\/j.drup.2022.100805_bib0660","doi-asserted-by":"crossref","first-page":"3608","DOI":"10.1182\/bloodadvances.2018023689","article-title":"Randomized trial of 10 days of decitabine +\/- bortezomib in untreated older patients with AML: CALGB 11002 (Alliance)","volume":"2","author":"Roboz","year":"2018","journal-title":"Blood Adv."},{"issue":"8","key":"10.1016\/j.drup.2022.100805_bib0665","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.3324\/haematol.2017.183418","article-title":"Phase I trial of plerixafor combined with decitabine in newly diagnosed older patients with acute myeloid leukemia","volume":"103","author":"Roboz","year":"2018","journal-title":"Haematologica"},{"issue":"11","key":"10.1016\/j.drup.2022.100805_bib0670","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1038\/sj.onc.1209377","article-title":"Cytochrome P450 pharmacogenetics and cancer","volume":"25","author":"Rodriguez-Antona","year":"2006","journal-title":"Oncogene"},{"issue":"5","key":"10.1016\/j.drup.2022.100805_bib0675","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1002\/ijc.26107","article-title":"The DNA methyltransferase inhibitors zebularine and decitabine induce mitochondria-mediated apoptosis and DNA damage in p53 mutant leukemic T cells","volume":"130","author":"Ruiz-Maga\u00f1a","year":"2012","journal-title":"Int. J. Cancer"},{"issue":"4","key":"10.1016\/j.drup.2022.100805_bib0680","first-page":"819","article-title":"Attempts to remodel the pathways of gemcitabine metabolism: recent approaches to overcoming tumours with acquired chemoresistance","volume":"3","author":"Saiki","year":"2020","journal-title":"Cancer Drug Resist."},{"issue":"1","key":"10.1016\/j.drup.2022.100805_bib0685","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1080\/09674845.2013.11669927","article-title":"DNA damage repair and tolerance: a role in chemotherapeutic drug resistance","volume":"70","author":"Salehan","year":"2013","journal-title":"Br. J. Biomed. Sci."},{"issue":"20","key":"10.1016\/j.drup.2022.100805_bib0690","doi-asserted-by":"crossref","first-page":"8127","DOI":"10.1158\/0008-5472.CAN-09-0458","article-title":"Azacytidine inhibits RNA methylation at DNMT2 target sites in human cancer cell lines","volume":"69","author":"Schaefer","year":"2009","journal-title":"Cancer Res."},{"issue":"15","key":"10.1016\/j.drup.2022.100805_bib0695","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1101\/gad.586710","article-title":"RNA methylation by Dnmt2 protects transfer RNAs against stress-induced cleavage","volume":"24","author":"Schaefer","year":"2010","journal-title":"Genes Dev."},{"issue":"5","key":"10.1016\/j.drup.2022.100805_bib0700","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1002\/ijc.20797","article-title":"5-Aza-2\u2032-deoxycytidine induces p21WAF expression by demethylation of p73 leading to p53-independent apoptosis in myeloid leukemia","volume":"114","author":"Schmelz","year":"2005","journal-title":"Int. J. Cancer"},{"issue":"3","key":"10.1016\/j.drup.2022.100805_bib0705","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/gcc.20193","article-title":"Acute myeloid leukemia with a complex aberrant karyotype is a distinct biological entity characterized by genomic imbalances and a specific gene expression profile","volume":"43","author":"Schoch","year":"2005","journal-title":"Genes Chromosomes Cancer"},{"issue":"8","key":"10.1016\/j.drup.2022.100805_bib0710","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.3324\/haematol.2018.207118","article-title":"A phase II study of guadecitabine in higher-risk myelodysplastic syndrome and low blast count acute myeloid leukemia after azacitidine failure","volume":"104","author":"S\u00e9bert","year":"2019","journal-title":"Haematologica"},{"issue":"12","key":"10.1016\/j.drup.2022.100805_bib0715","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1038\/sj.leu.2404439","article-title":"DNA repair contributes to the drug-resistant phenotype of primary acute myeloid leukaemia cells with FLT3 internal tandem duplications and is reversed by the FLT3 inhibitor PKC412","volume":"20","author":"Seedhouse","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.drup.2022.100805_bib0720","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2020.100712","article-title":"Inhibiting the inhibitors: targeting anti-apoptotic proteins in cancer and therapy resistance","volume":"52","author":"Shahar","year":"2020","journal-title":"Drug Resist. Updates"},{"key":"10.1016\/j.drup.2022.100805_bib0725","doi-asserted-by":"crossref","DOI":"10.1038\/nature22993","article-title":"Tracing the origins of relapse in acute myeloid leukaemia to stem cells","author":"Shlush","year":"2017","journal-title":"Nature"},{"issue":"10147","key":"10.1016\/j.drup.2022.100805_bib0730","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S0140-6736(18)31041-9","article-title":"Acute myeloid leukaemia","volume":"392","author":"Short","year":"2018","journal-title":"Lancet"},{"issue":"6817","key":"10.1016\/j.drup.2022.100805_bib0735","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/35051606","article-title":"Inactivation of the apoptosis effector Apaf-1 in malignant melanoma","volume":"409","author":"Soengas","year":"2001","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.drup.2022.100805_bib0740","doi-asserted-by":"crossref","first-page":"2952","DOI":"10.1172\/JCI119848","article-title":"Aberrant nuclear factor-\u03bab\/Rel expression and the pathogenesis of breast cancer","volume":"100","author":"Sovak","year":"1997","journal-title":"J. Clin. Invest."},{"issue":"4","key":"10.1016\/j.drup.2022.100805_bib0745","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.exphem.2013.12.004","article-title":"Mechanisms of resistance to azacitidine in human leukemia cell lines","volume":"42","author":"Sripayap","year":"2014","journal-title":"Exp. Hematol."},{"issue":"47","key":"10.1016\/j.drup.2022.100805_bib0750","article-title":"Myelodysplastic syndromes current treatment algorithm 2018","volume":"8","author":"Steensma","year":"2018","journal-title":"Blood Cancer J."},{"issue":"9","key":"10.1016\/j.drup.2022.100805_bib0755","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/cddis.2013.320","article-title":"Smac mimetic and demethylating agents synergistically trigger cell death in acute myeloid leukemia cells and overcome apoptosis resistance by inducing necroptosis","volume":"4","author":"Steinhart","year":"2013","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.drup.2022.100805_bib0760","doi-asserted-by":"crossref","DOI":"10.1053\/j.seminhematol.2019.02.001","article-title":"Can we predict responsiveness to hypomethylating agents in AML?","volume":"56","author":"Stomper","year":"2019","journal-title":"Semin. Hematol."},{"key":"10.1016\/j.drup.2022.100805_bib0765","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2021.100777","article-title":"Novel nanomedicines to overcome cancer multidrug resistance","volume":"58","author":"Su","year":"2021","journal-title":"Drug Resist. Updates"},{"issue":"2","key":"10.1016\/j.drup.2022.100805_bib0770","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1007\/s11899-015-0253-6","article-title":"Role of microenvironment in resistance to therapy in AML","volume":"10","author":"Tabe","year":"2015","journal-title":"Curr. Hematol. Malig. Rep."},{"issue":"5","key":"10.1016\/j.drup.2022.100805_bib0775","first-page":"1796","article-title":"Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias","volume":"6","author":"Tamm","year":"2000","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.drup.2022.100805_bib0780","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/sj.thj.6200549","article-title":"XIAP expression correlates with monocytic differentiation in adult de novo AML: impact on prognosis","volume":"5","author":"Tamm","year":"2004","journal-title":"Hematol. J."},{"issue":"14","key":"10.1016\/j.drup.2022.100805_bib0785","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.4161\/cc.10.14.16399","article-title":"Hypomethylating agents reactivate FOXO3A in acute myeloid leukemia","volume":"10","author":"Th\u00e9pot","year":"2011","journal-title":"Cell Cycle"},{"issue":"3","key":"10.1016\/j.drup.2022.100805_bib0790","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1093\/annonc\/mdr280","article-title":"Correlation of cytidine deaminase polymorphisms and activity with clinical outcome in gemcitabine-\/platinum-treated advanced non-small-cell lung cancer patients","volume":"23","author":"Tibaldi","year":"2012","journal-title":"Ann. Oncol."},{"issue":"12","key":"10.1016\/j.drup.2022.100805_bib0795","doi-asserted-by":"crossref","first-page":"571","DOI":"10.3727\/096504013X13775486749371","article-title":"Synergistic effect of 5-azacytidine and NF-kB inhibitor DHMEQ on apoptosis induction in myeloid leukemia cells","volume":"20","author":"Togano","year":"2013","journal-title":"Oncol. Res."},{"issue":"8","key":"10.1016\/j.drup.2022.100805_bib0800","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1248\/bpb.b14-00622","article-title":"Cellular uptake of decitabine by equilibrative nucleoside transporters in HCT116 cells","volume":"38","author":"Ueda","year":"2015","journal-title":"Biol. Pharm. Bull."},{"issue":"4","key":"10.1016\/j.drup.2022.100805_bib0805","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1038\/leu.2017.340","article-title":"AZA-MS: a novel multiparameter mass spectrometry method to determine the intracellular dynamics of azacitidine therapy in vivo","volume":"32","author":"Unnikrishnan","year":"2018","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.drup.2022.100805_bib0810","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1038\/leu.2013.330","article-title":"Expression of nucleoside-metabolizing enzymes in myelodysplastic syndromes and modulation of response to azacitidine","volume":"28","author":"Valencia","year":"2014","journal-title":"Leukemia"},{"issue":"29","key":"10.1016\/j.drup.2022.100805_bib0815","doi-asserted-by":"crossref","first-page":"47103","DOI":"10.18632\/oncotarget.17482","article-title":"BCL2L10 positive cells in bone marrow are an independent prognostic factor of azacitidine outcome in myelodysplastic syndrome and acute myeloid leukemia","volume":"8","author":"Vidal","year":"2017","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.drup.2022.100805_bib0820","doi-asserted-by":"crossref","first-page":"613","DOI":"10.3324\/haematol.2013.099549","article-title":"Why methylation is not a marker predictive of response to hypomethylating agents","volume":"99","author":"Voso","year":"2014","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.drup.2022.100805_bib0825","first-page":"771","article-title":"Cell death response to dna damage","volume":"92","author":"Wang","year":"2019","journal-title":"Yale J. Biol. Med."},{"issue":"4","key":"10.1016\/j.drup.2022.100805_bib0830","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1038\/7410","article-title":"Control of inducible chemoresistance: Enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-\u03baB","volume":"5","author":"Wang","year":"1999","journal-title":"Nat. Med."},{"key":"10.1016\/j.drup.2022.100805_bib0835","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2021.100743","article-title":"Multidrug resistance proteins (MRPs): structure, function and the overcoming of cancer multidrug resistance","volume":"54","author":"Wang","year":"2021","journal-title":"Drug Resist. Updates"},{"issue":"5","key":"10.1016\/j.drup.2022.100805_bib0840","doi-asserted-by":"crossref","first-page":"379","DOI":"10.4161\/cbt.23761","article-title":"Chemotherapy induced DNA damage response","volume":"14","author":"Woods","year":"2013","journal-title":"Cancer Biol. Ther."},{"issue":"2","key":"10.1016\/j.drup.2022.100805_bib0845","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.leukres.2014.08.016","article-title":"The hENT1 and DCK genes underlie the decitabine response in patients with myelodysplastic syndrome","volume":"39","author":"Wu","year":"2015","journal-title":"Leuk. Res."},{"issue":"66","key":"10.1016\/j.drup.2022.100805_bib0850","first-page":"1","article-title":"High expression of the human equilibrative nucleoside transporter 1 gene predicts a good response to decitabine in patients with myelodysplastic syndrome","volume":"16","author":"Wu","year":"2016","journal-title":"J. Transl. Med."},{"issue":"3","key":"10.1016\/j.drup.2022.100805_bib0855","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2015808118","article-title":"ACTL6A promotes repair of cisplatin-induced DNA damage, a new mechanism of platinum resistance in cancer","volume":"118","author":"Xiao","year":"2021","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"11","key":"10.1016\/j.drup.2022.100805_bib0860","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0079106","article-title":"Panobinostat enhances cytarabine and daunorubicin sensitivities in AML cells through suppressing the expression of BRCA1, CHK1, and Rad51","volume":"8","author":"Xie","year":"2013","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.drup.2022.100805_bib0865","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-11795-5","article-title":"hCINAP regulates the DNA-damage response and mediates the resistance of acute myelocytic leukemia cells to therapy","volume":"10","author":"Xu","year":"2019","journal-title":"Nat. Commun."},{"issue":"22","key":"10.1016\/j.drup.2022.100805_bib0870","doi-asserted-by":"crossref","first-page":"4239","DOI":"10.1200\/JCO.2003.06.001","article-title":"Overcoming drug resistance in multiple myeloma: the emergence of therapeutic approaches to induce apoptosis","volume":"21","author":"Yang","year":"2003","journal-title":"J. Clin. Oncol."},{"issue":"13","key":"10.1016\/j.drup.2022.100805_bib0875","doi-asserted-by":"crossref","first-page":"6400","DOI":"10.1158\/0008-5472.CAN-07-0251","article-title":"Delivery of 5-aza-2\u2032-deoxycytidine to cells using oligodeoxynucleotides","volume":"67","author":"Yoo","year":"2007","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.drup.2022.100805_bib0880","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1042\/BST20160038","article-title":"The SLC28 (CNT) and SLC29 (ENT) nucleoside transporter families: a 30-year collaborative odyssey","volume":"44","author":"Young","year":"2016","journal-title":"Biochem. Soc. Trans."},{"issue":"2","key":"10.1016\/j.drup.2022.100805_bib0885","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.18632\/oncotarget.2732","article-title":"Lysosomal sequestration of hydrophobic weak base chemotherapeutics triggers lysosomal biogenesis and lysosomedependent cancer multidrug resistance","volume":"6","author":"Zhitomirsky","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.drup.2022.100805_bib0890","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.drup.2015.11.004","article-title":"Lysosomes as mediators of drug resistance in cancer","volume":"24","author":"Zhitomirsky","year":"2016","journal-title":"Drug Resist. Updates"},{"issue":"28","key":"10.1016\/j.drup.2022.100805_bib0895","doi-asserted-by":"crossref","first-page":"45117","DOI":"10.18632\/oncotarget.15155","article-title":"Lysosomal accumulation of anticancer drugs triggers lysosomal exocytosis","volume":"8","author":"Zhitomirsky","year":"2017","journal-title":"Oncotarget"}],"container-title":["Drug Resistance Updates"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1368764622000085?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1368764622000085?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T04:58:45Z","timestamp":1761281925000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1368764622000085"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":179,"alternative-id":["S1368764622000085"],"URL":"https:\/\/doi.org\/10.1016\/j.drup.2022.100805","relation":{},"ISSN":["1368-7646"],"issn-type":[{"value":"1368-7646","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Different mechanisms of drug resistance to hypomethylating agents in the treatment of myelodysplastic syndromes and acute myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"Drug Resistance Updates","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drup.2022.100805","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100805"}}